Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study is carried out to assess whether dapagliflozin improves glycemic control,
decreases fasting plasma glucose levels, body weight and blood pressure when added to
patient's existing medications and how it compares with their usual treatment without added
dapagliflozin. Safety data will be collected and analysed to confirm that treatment with
dapagliflozin is safe and well tolerated in patients who have diabetes and cardiovascular
disease